Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 95 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: norgestrel Clear all

Conditions: Pregnancy Prevention
Interventions: DR-103; Drug
Lead sponsor: Teva Women's Health; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 3,597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 94
States / cities: Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 83 more

Conditions: Contraception
Interventions: Levonorgestrel IUD; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Salt Lake City, Utah

Conditions: Dyslipidaemia
Interventions: AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy Females
Interventions: PF-04965842, Ethinyl estradiol (EE) and levonorgestrel (LN); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Emergency Contraception
Interventions: CDB-2914, levonorgestrel; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,672 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2001
U.S. locations: 6
States / cities: Los Angeles, California • Denver, Colorado • New York, New York + 3 more

Conditions: Breakthrough Bleeding
Interventions: DR-1031, Seasonale®, Portia®; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 567 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 50
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more

Conditions: HIV Infections, Tuberculosis
Interventions: Levonorgestrel (LNG); Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 16 Years and older · Female only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Chicago, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more

Conditions: Ovarian Carcinoma
Interventions: Laboratory Biomarker Analysis, Levonorgestrel, Placebo; Other · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 30 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 66
States / cities: Duarte, California • Los Angeles, California • Orange, California + 46 more

Conditions: Contraception
Interventions: Ulipristal Acetate, Levonorgestrel (LNG)/Ethinyl estradiol birth control pill; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Menorrhagia
Interventions: Levonorgestrel 52 mg intrauterine system; Combination Product
Lead sponsor: Medicines360; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 29
States / cities: Scottsdale, Arizona • Sacramento, California • San Diego, California + 25 more

Conditions: Contraception
Interventions: Lidocaine, Lubricant; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: Female only
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Contraception
Interventions: Kyleena; Drug
Lead sponsor: Bayer; Industry
Eligibility: Female only
Enrollment: 1,134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 12
States / cities: Lakewood, Colorado • Sarasota, Florida • Wellington, Florida + 9 more

Conditions: Contraception
Interventions: Norgestrel 0.075 mg; Drug
Lead sponsor: HRA Pharma; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Sacramento, California • Portland, Oregon

Conditions: Endometrial Cancer
Interventions: medroxyprogesterone, ethinyl estradiol, norgestrel, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: LY4515100 via SAD, LY4515100 via MAD, LY4515100, Itraconazole, Caffeine, Digoxin, Iohexol, Metformin, Rosuvastatin, Placebo, Midazolam, Levonorgestrel, Ethinyl Estradiol; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Residual Drug Amount of EE and LNG
Interventions: Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System; Drug
Lead sponsor: Insud Pharma; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy
Interventions: EE 30mcg/LNG 150mcg, Placebo; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 14 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Sacramento, California • St Louis, Missouri

Conditions: Chronic Hepatitis B
Interventions: ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Epilepsy, Contraception
Interventions: levonorgestrel IUS; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE); Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Healthy Adults
Interventions: PF-06882961, Atorvastatin, Midazolam, Levonorgestrel & Ethinyl Estradiol; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Oral Hormonal Contraceptive Use, Neural Activity, Mood, Hedonic Function
Interventions: Levonorgestrel/ethinyl estradiol, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pregnancy Prevention
Interventions: Levonorgestrel 1.5 milligram, Meloxicam 15 milligram, calcium carbonate 750 milligram; Drug · Other
Lead sponsor: InnovaGyn, Inc.; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Obesity
Interventions: Levonorgestrel 1.5mg by mouth once; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy

BLIS - Breastfeeding Levonorgestrel IUD Study

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

Efficacy Trial of CDB 2914 for Emergency Contraception

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

Impact of Combined Hormonal Contraceptives on UPA

Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

Topical Lidocaine on the Cervix and Intra-Cervical Prior to Insertion of Intrauterine Devices

KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method

Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

A Study of LY4515100 in Healthy Participants

A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System

Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

Contraceptive Hormone and Reward Measurement (CHARM Study)

Phase II Study of Ovulation in Obese Women

Effects of Obesity on Pharmacokinetics of the Levonorgestrel Emergency Contraceptive Pill